{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T14:12:42Z","timestamp":1768486362633,"version":"3.49.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.clml.2017.10.001","type":"journal-article","created":{"date-parts":[[2017,10,12]],"date-time":"2017-10-12T18:12:25Z","timestamp":1507831945000},"page":"e41-e50","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Management of Advanced and Relapsed\/Refractory Extranodal Natural Killer T-Cell Lymphoma: An Analysis of Stem Cell Transplantation and Chemotherapy Outcomes"],"prefix":"10.1016","volume":"18","author":[{"given":"Jonathan E.","family":"Brammer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dai","family":"Chihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. Michelle","family":"Poon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Caimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcos","family":"de Lima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Celina","family":"Ledesma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriela","family":"Rondon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan O.","family":"Ciurea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yago","family":"Nieto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Fanale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bouthaina","family":"Dabaja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard T.","family":"Maziarz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard E.","family":"Champlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chitra","family":"Hosing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Oki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2017.10.001_bib1","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.10.001_bib2","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1080\/10428190802455867","article-title":"Incidence and outcomes of the peripheral T-cell lymphoma subtypes in the United States","volume":"49","author":"Abouyabis","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2017.10.001_bib3","doi-asserted-by":"crossref","first-page":"3931","DOI":"10.1182\/blood-2008-10-185256","article-title":"Clinical differences between nasal and extranasal natural killer\/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project","volume":"113","author":"Au","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.10.001_bib4","doi-asserted-by":"crossref","first-page":"4997","DOI":"10.1182\/blood-2013-01-453233","article-title":"How I treat NK\/T-cell lymphomas","volume":"121","author":"Tse","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.10.001_bib5","series-title":"Tumours of Haematopoietic and Lymphoid Malignancies. World Health Organization Classification of Tumours","first-page":"285","author":"Chan","year":"2008"},{"key":"10.1016\/j.clml.2017.10.001_bib6","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S1470-2045(15)00533-1","article-title":"A\u00a0prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis","volume":"17","author":"Kim","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2017.10.001_bib7","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1002\/1097-0142(19951201)76:11<2351::AID-CNCR2820761125>3.0.CO;2-1","article-title":"Frequent expression of P-glycoprotein\/MDR1 by nasal T-cell lymphoma cells","volume":"76","author":"Yamaguchi","year":"1995","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2017.10.001_bib8","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1023\/A:1011144911781","article-title":"CHOP followed by involved field radiation: is it optimal for localized nasal natural killer\/T-cell lymphoma?","volume":"12","author":"Kim","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2017.10.001_bib9","doi-asserted-by":"crossref","first-page":"4410","DOI":"10.1200\/JCO.2011.35.6287","article-title":"Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)\/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study","volume":"29","author":"Yamaguchi","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.10.001_bib10","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1182\/blood-2012-05-431460","article-title":"SMILE for natural killer\/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group","volume":"120","author":"Kwong","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.10.001_bib11","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1016\/j.bbmt.2008.09.014","article-title":"Autologous hematopoietic stem cell transplantation in extranodal natural killer\/T cell lymphoma: a multinational, multicenter, matched controlled study","volume":"14","author":"Lee","year":"2008","journal-title":"Biol Blood Marrow Transpl"},{"key":"10.1016\/j.clml.2017.10.001_bib12","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/bmt.2009.239","article-title":"High-dose chemotherapy and hematopoietic SCT in the management of natural killer-cell malignancies","volume":"44","author":"Kwong","year":"2009","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.clml.2017.10.001_bib13","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.3109\/10428194.2011.572322","article-title":"Allogeneic hematopoietic stem cell transplantation for advanced extranodal natural killer\/T-cell lymphoma, nasal type","volume":"52","author":"Ennishi","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2017.10.001_bib14","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1365-2141.2005.05651.x","article-title":"Allogeneic haematopoietic stem cell transplantation as a promising treatment for natural killer-cell neoplasms","volume":"130","author":"Murashige","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2017.10.001_bib15","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"El","year":"1958","journal-title":"J\u00a0Am Stat Assoc"},{"key":"10.1016\/j.clml.2017.10.001_bib16","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.clml.2017.10.001_bib17","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1080\/10428194.2016.1180689","article-title":"Encouraging experience in the treatment of nasal type extra-nodal NK\/T-cell lymphoma in a non-Asian population","volume":"57","author":"Qi","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2017.10.001_bib18","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1038\/bmt.2014.65","article-title":"Allogeneic haematopoietic SCT for natural killer\/T-cell lymphoma: a multicentre analysis from the Asia Lymphoma Study Group","volume":"49","author":"Tse","year":"2014","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.clml.2017.10.001_bib19","first-page":"29","article-title":"Diagnostic and prognostic implications of circulating cell-free Epstein-Barr virus DNA in natural killer\/T-cell lymphoma","volume":"8","author":"Lei","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2017.10.001_bib20","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1182\/blood-2012-06-435024","article-title":"Clinical implications of plasma Epstein-Barr virus DNA in early-stage extranodal nasal-type NK\/T-cell lymphoma patients receiving primary radiotherapy","volume":"120","author":"Wang","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.10.001_bib21","doi-asserted-by":"crossref","first-page":"3250","DOI":"10.1158\/1078-0432.CCR-06-2373","article-title":"Effect of positive bone marrow EBV in situ hybridization in staging and survival of localized extranodal natural killer\/T-cell lymphoma, nasal-type","volume":"13","author":"Lee","year":"2007","journal-title":"Clin Cancer Res"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265017307784?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265017307784?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:30:37Z","timestamp":1761870637000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265017307784"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S2152265017307784"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2017.10.001","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of Advanced and Relapsed\/Refractory Extranodal Natural Killer T-Cell Lymphoma: An Analysis of Stem Cell Transplantation and Chemotherapy Outcomes","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2017.10.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}